New research recommends that doctors test the sera of patients with idiopathic pulmonary fibrosis for anti-neutrophil cytoplasmic antibodies (ANCA), as well as closely monitor this population for signs of lung vasculitis…
Search results for: FLARE
Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies
Due to a lawsuit, the FDA has issued only tentative approval for an extended-release oxycodone capsule. Obinutuzumab is in clinical trials for lupus nephritis, and subcutaneous belimumab is being tested for SLE…
New Gout Criteria from the ACR/EULAR Focus on Clinical Trials, Global Standards
Gout affects nearly 4% of American adults, causing joint inflammation, pain and crystal deposits that may lead to bone erosion over time. At least five different classification criteria for gout are used worldwide, creating potential discrepancies in clinical trial enrollment and eventual results. An international panel of investigators collaborated to create new, standardized gout classification…
Rheumatologist Steven S. Overman Reflects on His Last Day of Practice, Future of Specialty
I am a few weeks post-retirement. Having written thank you notes and completed urgent home projects, I swing in a hammock at our currently fire-threatened cabin north of Winthrop, Wash., and reflect. I feel like a young boy while freely flipping pages of a hand-scribed picture book, The Principles of Uncertainty, by Maira Kalman. She…
Genetic Screening May Prevent Adverse Gout Treatment Reaction
Screening gout patients for the HLA-B*58:01 allele may help rheumatologists determine more effective treatments and a patient’s risk of allopurinol-induced severe cutaneous adverse reactions…
FDA Reviewers Question Safety of AstraZeneca’s Gout Drug
(Reuters)—The U.S. Food and Drug Administration staff reviewers have raised concerns about kidney- and heart-related side effects noted in trials on AstraZeneca Plc’s gout treatment, especially at higher doses. FDA reviewers, in a preliminary review published on Wednesday, expressed concerns over higher death rates related to the side effects in patients who took the drug,…
Arthritis Power App Can Help Patients Monitor Symptoms, Improve Office Visits
For the past 16 years, the website, creakyjoints.org, founded by arthritis patient Seth Ginsberg and social entrepreneur Louis Tharp, has offered arthritis patients and their families a safe online community where they can receive meaningful support and education. In March, the online portal added a new initiative—Arthritis Power, the first-ever patient-led, patient-generated, app-based research registry…
FOCIS 2015: Research Increases Understanding of Lupus, RA
The field of rheumatology took center stage when a handful of speakers discussed trends and research during a disease-oriented session of the 2015 Federation of Clinical Immunity Societies (FOCIS 2015) conference held in San Diego in June. Neutrophils in SLE Mariana Kaplan, MD, chief of Systemic Autoimmunity Branch at the National Institute of Arthritis and…
Tabalumab Modestly Effective in Systemic Lupus Erythematosus
NEW YORK (Reuters Health)—Tabalumab, a monoclonal antibody to B-cell activating factor, was modestly better than placebo in relieving symptoms of systemic lupus erythematosus (SLE), according to results from the ILLUMINATE-2 trial. “Lupus is a complicated disease that does not behave the same way in all patients who share the clinical symptoms,” Dr. Joan T. Merrill…
Preparing Immunocompromised Patients for Risks of Traveling Abroad
Summer is a season for travel, so if your immunocompromised patients plan to journey to regions where there are outbreaks of infections, such as chikungunya, tuberculosis, typhoid, yellow fever or other diseases, communication and preparation may prevent serious health events. “The world teems with disease-causing organisms, and almost every infection is more serious in the…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 65
- Next Page »